GSK 2024 J.P. Morgan Healthcare Conference Presentation

GlaxoSmithKline presented at the J.P. Morgan Healthcare Conference in January 2024, highlighting double-digit sales and adjusted operating profit growth in Q3 and 9 months 2023. The presentation focused on momentum in Vaccines and Specialty Medicines, including the launch of Arexvy, the first-ever RSV vaccine, and £7.8 billion in sales from products launched since 2017.